Mutant IDH1: an immunotherapeutic target in tumors
The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mut...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
07 Jan 2015
|
| In: |
OncoImmunology
Year: 2014, Volume: 3, Issue: 12 |
| ISSN: | 2162-402X |
| DOI: | 10.4161/2162402X.2014.974392 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.4161/2162402X.2014.974392
|
| Author Notes: | Theresa Schumacher, Lukas Bunse, Wolfgang Wick, and Michael Platten |
| Summary: | The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+ antitumor T cell response in patients and a syngeneic tumor model in MHC-humanized mice. |
|---|---|
| Item Description: | Gesehen am 20.07.2020 |
| Physical Description: | Online Resource |
| ISSN: | 2162-402X |
| DOI: | 10.4161/2162402X.2014.974392 |